These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 19631713

  • 1. Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function.
    Erhardt JA, Erickson-Miller CL, Aivado M, Abboud M, Pillarisetti K, Toomey JR.
    Exp Hematol; 2009 Sep; 37(9):1030-7. PubMed ID: 19631713
    [Abstract] [Full Text] [Related]

  • 2. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
    Matsuki E, Miyakawa Y, Yamane A, Okamoto S.
    Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
    [Abstract] [Full Text] [Related]

  • 3. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
    Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM.
    Stem Cells; 2009 Feb; 27(2):424-30. PubMed ID: 19038790
    [Abstract] [Full Text] [Related]

  • 4. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
    Mitchell WB, Pinheiro MP, Boulad N, Kaplan D, Edison MN, Psaila B, Karpoff M, White MJ, Josefsson EC, Kile BT, Bussel JB.
    Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
    [Abstract] [Full Text] [Related]

  • 5. Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.
    Sun H, Tsai Y, Nowak I, Liesveld J, Chen Y.
    Stem Cell Res; 2012 Sep; 9(2):77-86. PubMed ID: 22683680
    [Abstract] [Full Text] [Related]

  • 6. A novel and simple hollow-fiber assay for in vivo evaluation of nonpeptidyl thrombopoietin receptor agonists.
    Xie CY, Xu YP, Zhao HB, Lou LG.
    Exp Hematol; 2012 May; 40(5):386-92. PubMed ID: 22269115
    [Abstract] [Full Text] [Related]

  • 7. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia.
    Haselboeck J, Kaider A, Pabinger I, Panzer S.
    Thromb Haemost; 2013 Apr; 109(4):676-83. PubMed ID: 23389750
    [Abstract] [Full Text] [Related]

  • 8. Revealing eltrombopag's promotion of human megakaryopoiesis through AKT/ERK-dependent pathway activation.
    Di Buduo CA, Currao M, Pecci A, Kaplan DL, Balduini CL, Balduini A.
    Haematologica; 2016 Dec; 101(12):1479-1488. PubMed ID: 27515246
    [Abstract] [Full Text] [Related]

  • 9. The non-peptide thrombopoietin receptor agonist eltrombopag stimulates megakaryopoiesis in bone marrow cells from patients with relapsed multiple myeloma.
    Jeong JY, Levine MS, Abayasekara N, Berliner N, Laubach J, Vanasse GJ.
    J Hematol Oncol; 2015 Apr 16; 8():37. PubMed ID: 25886818
    [Abstract] [Full Text] [Related]

  • 10. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
    Kühne T, Imbach P.
    Ann Hematol; 2010 Jul 16; 89 Suppl 1():67-74. PubMed ID: 20405290
    [Abstract] [Full Text] [Related]

  • 11. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients.
    Di Buduo CA, Laurent PA, Zaninetti C, Lordier L, Soprano PM, Ntai A, Barozzi S, La Spada A, Biunno I, Raslova H, Bussel JB, Kaplan DL, Balduini CL, Pecci A, Balduini A.
    Elife; 2021 Jun 01; 10():. PubMed ID: 34059198
    [Abstract] [Full Text] [Related]

  • 12. Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways.
    Baker JE, Su J, Koprowski S, Dhanasekaran A, Aufderheide TP, Gross GJ.
    J Pharmacol Exp Ther; 2015 Mar 01; 352(3):429-37. PubMed ID: 25512369
    [Abstract] [Full Text] [Related]

  • 13. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.
    Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL.
    Blood; 2007 Jun 01; 109(11):4739-41. PubMed ID: 17327409
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Eltrombopag in chronic hepatitis C.
    Mihăilă RG, Cipăian RC.
    World J Gastroenterol; 2014 Sep 21; 20(35):12517-21. PubMed ID: 25253952
    [Abstract] [Full Text] [Related]

  • 16. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
    Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, Aivado MA, Verma A, Steidl U.
    Blood; 2009 Oct 29; 114(18):3899-908. PubMed ID: 19710504
    [Abstract] [Full Text] [Related]

  • 17. Eltrombopag: the discovery of a second generation thrombopoietin-receptor agonist.
    Stasi R.
    Expert Opin Drug Discov; 2009 Jan 29; 4(1):85-93. PubMed ID: 23480339
    [Abstract] [Full Text] [Related]

  • 18. The biology of thrombopoietin and thrombopoietin receptor agonists.
    Kuter DJ.
    Int J Hematol; 2013 Jul 29; 98(1):10-23. PubMed ID: 23821332
    [Abstract] [Full Text] [Related]

  • 19. Thrombopoietin amplifies ADP-induced HSP27 phosphorylation in human platelets: importance of pre-treatment.
    Cuong NT, Doi T, Matsushima-Nishiwaki R, Akamatsu S, Kuroyanagi G, Kondo A, Mizutani J, Wada I, Otsuka T, Tokuda H, Kozawa O, Ogura S.
    Int J Mol Med; 2013 Jun 29; 31(6):1291-7. PubMed ID: 23588296
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist.
    Xie C, Zhao H, Bao X, Fu H, Lou L.
    J Cell Mol Med; 2018 Nov 29; 22(11):5367-5377. PubMed ID: 30156363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.